Get started
000

EGETIS THERAPEUTICS AB NPV

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

0ABW chart


Full chart

0ABW upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.86 B‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.10 SEK
Net income (FY)
‪−326.90 M‬ SEK
Revenue (FY)
‪57.60 M‬ SEK
Shares float
‪194.07 M‬
Beta (1Y)
0.38

Employees


Employees (FY)
28
Change (1Y)
+11 +64.71%
Revenue / Employee (1Y)
‪203.04 K‬ SEK
Net income / Employee (1Y)
‪−1.15 M‬ SEK

About EGETIS THERAPEUTICS AB


Sector
Health Technology
CEO
Nicklas Westerholm
Headquarters
Stockholm
Website
egetis.com
Founded
2006
ISIN
SE0003815604
FIGI
BBG01DD5Y685
Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. Its projects include Emcitate for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The company was founded by Torsten Almén, Heidi Brurok, Louis J. Ignarro, Per Jynge, Jan Olof Gustav Karlsson, Ingemar Lundström, and Rob Towart in 2006 and is headquartered in Stockholm, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0ABW news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0ABW is 5.12 SEK — it has decreased by −3.76% in the past 24 hours. Watch EGETIS THERAPEUTICS AB NPV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange EGETIS THERAPEUTICS AB NPV stocks are traded under the ticker 0ABW.
0ABW stock has risen by 6.44% compared to the previous week, the month change is a 20.75% rise, over the last year EGETIS THERAPEUTICS AB NPV has showed a −2.66% decrease.
We've gathered analysts' opinions on EGETIS THERAPEUTICS AB NPV future price: according to them, 0ABW price has a max estimate of 14.50 SEK and a min estimate of 10.00 SEK. Watch 0ABW chart and read a more detailed EGETIS THERAPEUTICS AB NPV stock forecast: see what analysts think of EGETIS THERAPEUTICS AB NPV and suggest that you do with its stocks.
0ABW reached its all-time high on Jun 10, 2024 with the price of 9.28 SEK, and its all-time low was 3.86 SEK and was reached on Jul 21, 2023. View more price dynamics on 0ABW chart.
See other stocks reaching their highest and lowest prices.
0ABW stock is 3.91% volatile and has beta coefficient of 0.38. Track EGETIS THERAPEUTICS AB NPV stock price on the chart and check out the list of the most volatile stocks — is EGETIS THERAPEUTICS AB NPV there?
Today EGETIS THERAPEUTICS AB NPV has the market capitalization of ‪1.86 B‬, it has increased by 13.91% over the last week.
Yes, you can track EGETIS THERAPEUTICS AB NPV financials in yearly and quarterly reports right on TradingView.
EGETIS THERAPEUTICS AB NPV is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
0ABW earnings for the last quarter are −0.28 SEK per share, whereas the estimation was −0.30 SEK resulting in a 5.52% surprise. The estimated earnings for the next quarter are −0.26 SEK per share. See more details about EGETIS THERAPEUTICS AB NPV earnings.
EGETIS THERAPEUTICS AB NPV revenue for the last quarter amounts to ‪9.40 M‬ SEK, despite the estimated figure of ‪15.65 M‬ SEK. In the next quarter, revenue is expected to reach ‪15.30 M‬ SEK.
0ABW net income for the last quarter is ‪−86.20 M‬ SEK, while the quarter before that showed ‪−71.90 M‬ SEK of net income which accounts for −19.89% change. Track more EGETIS THERAPEUTICS AB NPV financial stats to get the full picture.
No, 0ABW doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 28.00 employees. See our rating of the largest employees — is EGETIS THERAPEUTICS AB NPV on this list?
Like other stocks, 0ABW shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EGETIS THERAPEUTICS AB NPV stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EGETIS THERAPEUTICS AB NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EGETIS THERAPEUTICS AB NPV stock shows the neutral signal. See more of EGETIS THERAPEUTICS AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.